Pfizer announced the results of an observational study that showed patients taking Lipitor (atorvastatin calcium) had a significant 13 per cent reduction in the relative risk of experiencing a cardiovascular event compared with patients taking simvastatin (Zocor) therapy. The patients in this study did not have evident cardiovascular disease and were newly initiated on either treatment. This study was performed in conjunction with HealthCore, WellPoint's health outcomes research subsidiary. Results of this study, from one of the largest US managed care claims databases with more than 219,000 adult patients, were published in the December issue of Mayo Clinic Proceedings. For more details referhttp://www.pharmabiz.com/article/detnews.asp?articleid=47292
No comments:
Post a Comment